EQUITY, SHARE-BASED COMPENSATION AND WARRANTS, Warrant Activity (Details) - USD ($)		1 Months Ended			3 Months Ended			6 Months Ended	9 Months Ended	12 Months Ended
	Feb. 14, 2017	Nov. 09, 2017	Aug. 31, 2017	Jun. 30, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2017	Dec. 31, 2016	Feb. 28, 2017	Jan. 31, 2017
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)		$ 2.21					$ 4.14		$ 4.14
Outstanding at end of period (in dollars per share)					$ 2.21			$ 4.14	$ 2.21	$ 4.14
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life									3 years 7 months 6 days	2 years 9 months 18 days
Increase in authorized number of shares of common stock (in shares)					50,000,000			50,000,000	50,000,000	50,000,000	50,000,000	25,000,000
Former Employee [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Common stock issued for former employee (in shares)	108,696
Cash paid in lieu of bonus	$ 100,000
Board of Directors Chairman [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Shares issued (in shares)				96,372
Transitional monthly compensation awarded							$ 8,333	$ 10,000
Transitional monthly compensation awarded in lieu of cash (in shares)							9,027	7,035
Director [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Shares issued (in shares)			35,336	345,205
Grant date fair value (in dollars per share)			$ 1.09	$ 0.90
Equity Warrants [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)		20,832,273					6,364,110		6,364,110
Issued (in shares)									0
Impact of repricing debenture purchaser warrants, Prior to repricing (in shares)									(875,000)
Impact of repricing debenture purchaser warrants, After repricing (in shares)									875,000
Impact of repricing subordinated note holder warrants, Prior to repricing (in shares)									(289,669)
Impact of repricing subordinated note holder warrants, After repricing (in shares)									289,669
Impact of anti-dilution clauses, Prior to impact (in shares)									0
Impact of anti-dilution clauses, After impact (in shares)									0
Transfer from liability to equity (in shares)									14,468,163
Exercised (in shares)									0
Forfeited, expired or cancelled (in shares)									0
Outstanding at end of period (in shares)					20,832,273			6,364,110	20,832,273	6,364,110
Exercisable at end of period (in shares)					20,832,273				20,832,273
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)		$ 2.32					$ 5.77		$ 5.77
Impact of repricing debenture purchaser warrants, Prior to repricing (in dollars per share)									5.49
Impact of repricing debenture purchaser warrants, After repricing (in dollars per share)									0.96
Impact of repricing subordinated note holder warrants, Prior to repricing (in dollars per share)									5.25
Impact of repricing subordinated note holder warrants, After repricing (in dollars per share)									0.96
Transfer from liability to equity (in dollars per share)									1.16
Outstanding at end of period (in dollars per share)					$ 2.32			$ 5.77	2.32	$ 5.77
Exercisable at end of period (in dollars per share)					$ 2.32				$ 2.32
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life									3 years 7 months 6 days	2 years 4 months 24 days
Impact of repricing debenture purchaser warrants, Prior to repricing									2 years 1 month 6 days
Impact of repricing debenture purchaser warrants, After repricing									5 years 6 months
Impact of repricing subordinated note holder warrants, Prior to repricing									3 years 3 months 18 days
Impact of repricing subordinated note holder warrants, After pricing									3 years 3 months 18 days
Transfer from liability to equity									4 years 9 months 18 days
Exercisable, weighted average remaining contractual life									3 years 7 months 6 days
Liability Warrants [Member]
Shares Under Warrants [Roll Forward]
Outstanding at beginning of period (in shares)		1,846,667					4,474,868		4,474,868
Issued (in shares)									11,783,163
Impact of repricing debenture purchaser warrants, Prior to repricing (in shares)									0
Impact of repricing debenture purchaser warrants, After repricing (in shares)									0
Impact of repricing subordinated note holder warrants, Prior to repricing (in shares)									0
Impact of repricing subordinated note holder warrants, After repricing (in shares)									0
Impact of anti-dilution clauses, Prior to impact (in shares)									(1,489,868)
Impact of anti-dilution clauses, After impact (in shares)									2,327,919
Transfer from liability to equity (in shares)									(14,468,163)
Exercised (in shares)									(781,252)
Forfeited, expired or cancelled (in shares)									0
Outstanding at end of period (in shares)					1,846,667			4,474,868	1,846,667	4,474,868
Exercisable at end of period (in shares)					1,846,667				1,846,667
Equity and Liability Warrants Outstanding, Weighted Average Exercise Price [Roll Forward]
Outstanding at beginning of period (in dollars per share)		$ 1.06					$ 1.82		$ 1.82
Issued (in dollars per share)									0.96
Impact of anti-dilution clauses, Prior to impact (in dollars per share)									1.50
Impact of anti-dilution clauses, After impact (in dollars per share)									0.96
Transfer from liability to equity (in dollars per share)									1.16
Exercised (in dollars per share)									0.96
Outstanding at end of period (in dollars per share)					$ 1.06			$ 1.82	1.06	$ 1.82
Exercisable at end of period (in dollars per share)					$ 1.06				$ 1.06
Equity and Liability Warrants, Additional Disclosures [Abstract]
Outstanding, weighted average remaining contractual life									8 months 12 days	3 years 3 months 18 days
Issued									5 years
Impact of anti-dilution clauses, Prior to impact									9 months 18 days
Impact of anti-dilution clauses, After impact									9 months 18 days
Transfer from liability to equity									4 years 9 months 18 days
Exercised									0 years
Exercisable, weighted average remaining contractual life									8 months 12 days
Series F Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)					2,186	315
Number of preferred stock for conversion (in shares)					2,186	315
Carrying value of preferred stock					$ 92,000			$ 0	$ 92,000	$ 0
Series G Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)					689	11
Number of preferred stock for conversion (in shares)					689	11
Carrying value of preferred stock					$ 646,000			$ 0	$ 646,000	$ 0
Series G Convertible Preferred Stock [Member] | Subsequent Event [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)		499
Number of preferred stock for conversion (in shares)		499
Common Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)					2,111,188	220,439			2,331,627
Number of preferred stock for conversion (in shares)					2,111,188	220,439			2,331,627
Carrying value of preferred stock to reclassified common stock					$ 700,000	$ 100,000
Stock price (in dollars per share)					$ 1.08				$ 1.08
Common Stock [Member] | Subsequent Event [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)		332,667
Number of preferred stock for conversion (in shares)		332,667
Preferred Stock [Member] | Subsequent Event [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Carrying value of preferred stock		$ 100,000
Preferred Stock [Member] | Series F Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)									(2,501)
Number of preferred stock for conversion (in shares)									(2,501)
Preferred Stock [Member] | Series G Convertible Preferred Stock [Member]
Equity and Liability Warrants, Additional Disclosures [Abstract]
Preferred shares converted into common stock (in shares)									(700)
Number of preferred stock for conversion (in shares)									(700)